NCT06193993View on ClinicalTrials.gov

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

September 5, 2023

Study Completion Date

September 30, 2026

Conditions
Prostate CancerMetastatic CancerHormone Sensitive Prostate CancerCastration-resistant Prostate Cancer
Interventions
DRUG

Abiraterone Acetate

Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
collaborator

National University of Singapore

OTHER

lead

National University Hospital, Singapore

OTHER